CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease

por Li, James, Arest, Sandra, Olszowy, Bartlomiej, Gordon, John, Barrero, Carlos A., Perez-Leal, Oscar
Publicado 2023